Novel pyrimidine-2,4-dione–1,2,3-triazole and furo[2,3-d]pyrimidine-2-one–1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation

European Journal of Medicinal Chemistry

Volumn 125, Issue , 2017, Pages 1247-1267

  Gregorić, Tomislav ^a   Sedić, Mirela ^b,c   Grbčić, Petra ^b   Tomljenović Paravić, Andrea ^b   Kraljević Pavelić, Sandra ^b,c   Cetina, Mario ^d   Vianello, Robert ^e   Raić Malić, Silvana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University of Rijeka   (Croatia)

^c UNIVERSITY OF RIJEKA   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

5 endo trig cyclization; Computational chemistry; Furo 2,3 d pyrimidine 2 one; Sphingolipid signaling; Wee 1 kinase; X ray analysis

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; 5 BROMO N 1,N 3 DI[4 [1 (4 CHLOROPHENYL) 1,2,3 TRIAZOL 4 YL]METHYL]PYRIMIDINE 2,4 DIONE; ALKYNE DERIVATIVE; ANTINEOPLASTIC AGENT; CERAMIDASE; COPPER; FLUOROURACIL; FURO[2,3 D]PYRIMIDINE DERIVATIVE; N 3 [(1 BENZYL 1,2,3 TRIAZOL 4 YL)METHYL] 6 (CYCLOPROPYL) 5 (CYCLOPROPYLETHYN 1 YL)FURO[2,3 D]PYRIMIDINE 2 ONE; PALLADIUM; PHOSPHOTRANSFERASE; PYRIMIDINE DERIVATIVE; SPHINGOLIPID; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; WEE 1 KINASE; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; TRIAZOLE DERIVATIVE; WEE1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CATALYSIS; CLICK CHEMISTRY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; CYTOSTASIS; DIMERIZATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MITOCHONDRIAL TOXICITY; REGIOSELECTIVITY; RING CLOSING METATHESIS; SIGNAL TRANSDUCTION; SONOGASHIRA REACTION; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HEP-G2 CELL LINE; METABOLISM; MOLECULAR MODEL; NEOPLASMS; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CATALYSIS; CELL CYCLE PROTEINS; CRYSTALLOGRAPHY, X-RAY; CYCLIZATION; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HEP G2 CELLS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; TRIAZOLES;

EID: 84995804525     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.11.028     Document Type: Article

References (81)

1. [1] Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Statistics, Cancer, 2007, CA Cancer. J. Clin. 57 (2007), 43–66.
2. [2] Zhu, S.L., Wu, Y., Liu, C.J., Wei, C.Y., Tao, J.C., Liu, H.M., Design and stereoselective synthesis of novel isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents. Eur. J. Med. Chem. 65 (2013), 70–82.
3. [3](a) Nepali, K., Sharma, S., Sharma, M., Bedi, P.M.S., Dhar, K.L., Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. Eur. J. Med. Chem. 77 (2014), 422–487.
4. [3](b) Gediya, L.K., Njar, V.C., Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin. Drug Discov. 4 (2009), 1099–1111.
5. [4](a) Pałasz, A., Ciez, D., In search of uracil derivatives as bioactive agents. Uracils and fused uracils: synthesis, biological activity and applications. Eur. J. Med. Chem. 97 (2015), 582–611.
6. [4](b) Mohamed, M.S., Youns, M.M., Ahmed, N.M., Synthesis, antimicrobial, antioxidant activities of novel 6-aryl-5-cyano thiouracil derivatives. Eur. J. Med. Chem. 69 (2013), 591–600.
7. [5](a) Chu, C.K., Baker, D.C., Nucleosides and Nucleotides as Antitumor and Antiviral Agents. 1993, Plenum Press, New York.
8. [5](b) Godefridus, J.P., Deoxynucleoside Analogs in Cancer Therapy. 2006, Humana Press, Totowa.
9. [5](c) Ferrero, M., Gotor, V., Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides, and C-Nucleosides. Chem. Rev. 100 (2000), 4319–4348.
10. [5](d) Townsend, L.B., Chemistry of Nucleosides and Nucleotides. 1994, Plenum Press, New York.
11. [5](e) Galmarini, C.M., Mackey, J.R., Dumontet, C., Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 3 (2002), 415–424.
12. [6](a) Martin-Kohler, A., Widmer, J., Bold, G., Meyer, T., Sequin, U., Traxler, P., Furo[2,3-d]pyrimidines and Oxazolo[5,4-d]pyrimidines as inhibitors of receptor tyrosine kinases (RTK). Helv. Chim. Acta 87 (2004), 956–975.
13. [6](b) Peng, Y.H., Shiao, H.Y., Tu, C.H., Liu, P.M., Hsu, J.T.A., Amancha, P.K., Wu, J.S., Coumar, M.S., Chen, C.H., Wang, S.Y., Lin, W.H., Sun, H.Y., Chao, Y.S., Lyu, P.C., Hsieh, H.P., Wu, S.Y., Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors,. J. Med. Chem. 56 (2013), 3889–3903.
14. [6](c) Zhang, L., Xin, M., Shen, H., Wen, J., Tang, F., Tu, C., Zhao, X., Wei, P., Five-membered heteroaromatic ring fused-pyrimidine derivatives: design, synthesis, and hedgehog signaling pathway inhibition study. Bioorg. Med. Chem. Lett. 24 (2014), 3486–3492.
15. [6](d) Shiao, H.Y., Coumar, M.S., Chang, C.W., Ke, Y.Y., Chi, Y.H., Chu, C.Y., Sun, H.Y., Chen, C.H., Lin, W.H., Fung, K.S., Kuo, P.C., Huang, C.T., Chang, K.Y., Lu, C.T., Hsu, J.T., Chen, C.T., Jiaang, W.T., Chao, Y.S., Hsieh, H.P., Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine aurora kinase inhibitor. J. Med. Chem. 56 (2013), 5247–5360.
16. [7] Jiao, X., Kopecky, D.J., Liu, J., Liu, J., Jaen, J.C., Cardozo, M.G., Sharma, R., Walker, N., Wesche, H., Li, S., Farrelly, E., Xiao, S.H., Wang, Z., Kayser, F., Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors. Bioorg. Med. Chem. Lett. 22 (2012), 6212–6217.
17. [8] Zhao, A., Gao, X., Wang, Y., Ai, J., Wang, Y., Chen, Y., Geng, M., Zhang, A., Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold. Bioorg. Med. Chem. 19 (2011), 3906–3918.
18. [9] Gazivoda, T., Šokčević, M., Kralj, M., Šuman, L., Pavelić, K., De Clercq, E., Andre, G., Snoeck, R., Balzarini, J., Mintas, M., Raić-Malić, S., Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4‘,5‘-didehydro-L-ascorbic acid derivatives. J. Med. Chem. 50 (2007), 4105–4112.
19. [10] Meščić, A., Harej, A., Klobučar, M., Glavač, D., Cetina, M., Kraljević Pavelić, S., Raić-Malić, S., Discovery of new acid ceramidase-targeted acyclic 5-alkynyl and 5-heteroaryl uracil nucleosides. ACS Med. Chem. Lett. 6 (2015), 1150–1155.
20. [11](a) Ogretmen, B., Hannun, Y.A., Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4 (2004), 604–616.
21. [11](b) Pizzirani, D., Pagliuca, C., Realini, N., Branduardi, D., Bottegoni, G., Mor, M., Bertozzi, F., Scarpelli, R., Piomelli, D., Bandiera, T., Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure–activity relationship (SAR). J. Med. Chem. 56 (2013), 3518–3530.
22. [12] Bonhoure, E., Lauret, A., Barnes, D.J., Martin, C., Malavaud, B., Kohama, T., Melo, J.V., Cuvillier, O., Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 22 (2008), 971–979.
23. [13] Realini, N., Solorzano, C., Pagliuca, C., Pizzirani, D., Armirotti, A., Luciani, R., Costi, M.P., Bandiera, T., Piomelli, D., Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci. Rep. 3 (2013), 1035–1042.
24. [14](a) Chinchilla, R., Nájera, C., The Sonogashira reaction: A booming methodology in synthetic organic chemistry. Chem. Rev. 107 (2007), 874–922.
25. [14](b) Janeba, Z., Holỳ, A., Pohl, R., Snoeck, R., Andrei, G., De Clercq, E., Balzarini, J., Synthesis and biological evaluation of acyclic nucleotide analogues with a furo[2,3-d]pyrimidin-2(3H)-one base. Can. J. Chem. 88 (2010), 628–638.
26. [14](c) Ang, W.J., Tai, C.H., Lo, L.C., Lam, Y., Palladium-catalyzed annulation of internal alkynes in aqueous medium. RSC Adv. 4 (2014), 4921–4929.
27. [14](d) Mahendar, L., Reddy, A.G.K., Krishn, J., Satyanarayana, G., [Cu]-Catalyzed domino Sonogashira coupling followed by intramolecular 5-exo-dig cyclization: synthesis of 1,3-dihydro-2-benzofurans. J. Org. Chem. 79 (2014), 8566–8576.
28. [15](a) Aucagne, V., Amblard, F., Agrofoglio, A., Highly efficient AgNO3-catalyzed preparation of substituted furanopyrimidine-nucleosides. Synlett, 2004, 2406–2408.
29. [15](b) Sniady, A., Durham, A., Morreale, M.S., Marcinek, A., Szafert, S., Lis, T., Brzezinska, K.R., Iwasaki, T., Ohshima, T., Mashima, K., Dembinski, R., Zinc-catalyzed cycloisomerizations. Synthesis of substituted furans and furopyrimidine nucleosides. J. Org. Chem. 73 (2008), 5881–5889.
30. [16] Fresneau, N., Hiebel, M.A., Agrofoglio, L.A., Berteina Raboin, S., One-pot Sonogashira-cyclization protocol to obtain substituted furopyrimidine nucleosides in aqueous conditions. Tetrahedron Lett. 53 (2012), 1760–1763.
31. [17](a) Raić-Malić, S., Meščić, A., Recent trends in 1,2,3-Triazolo-nucleosides as promising anti-infective and anticancer agents. Curr. Med. Chem. 22 (2015), 1462–1499.
32. [17](b) Saftić, D., Vianello, R., Žinić, B., 5-Triazolyluracils and their N1-sulfonyl derivatives: intriguing reactivity differences in the sulfonation of triazole N1′-substituted and N1′-unsubstituted uracil molecules. Eur. J. Org. Chem. 35 (2015), 7695–7704.
33. [18] Kolb, H.C., Sharpless, K.B., The growing impact of click chemistry on drug discovery, Drug Discov. Today 8 (2003), 1128–1137.
34. [19](a) Zhang, J., Zhang, H., Cai, W.X., Yu, L.P., Zhen, X.C., Zhang, A., ‘Click’ D1 receptor agonists with a 5-HT1A receptor pharmacophore producing D2 receptor activity. Bioorg. Med. Chem. 17 (2009), 4873–4880.
35. [19](b) Jagasia, R., Holub, J.M., Bollinger, M., Kirshenbaum, K., Finn, M.G., Peptide cyclization and cyclodimerization by CuI-mediated azide−alkyne cycloaddition. J. Org. Chem. 74 (2009), 2964–2974.
36. [19](c) Huber, D., Hubner, H., Gmeiner, P., 1,1′-disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands. J. Med. Chem. 52 (2009), 6860–6870.
37. [20] Głowacka, I.E., Balzarini, J., Wróblewski, A.E., The synthesis, antiviral, cytostatic and cytotoxic evaluation of a new series of acyclonucleotide analogues with a 1,2,3-triazole linker. Eur. J. Med. Chem. 70 (2013), 703–722.
38. [21](a) Montagu, A., Roy, V., Balzarini, J., Snoeck, R., Andrei, G., Agrofoglio, L.A., Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2′-deoxyuridines and their antiviral evaluation. Eur. J. Med. Chem. 46 (2011), 778–786.
39. [21](b) Lee, Y.S., Park, S.M., Kim, H.M., Park, S.K., Lee, K., Lee, C.W., Kim, B.H., C5-Modified nucleosides exhibiting anticancer activity. Bioorg. Med. Chem. Lett. 19 (2009), 4688–4691.
40. [21](c) Park, S.M., Yang, H., Park, S.K., Kim, H.M., Kim, B.H., Design, synthesis, and anticancer activities of novel perfluoroalkyltriazole-appended 2'-deoxyuridines. Bioorg. Med. Chem. Lett. 20 (2010), 5831–5834.
41. [22](a) Yu, J.L., Wu, Q.P., Zhang, Q.S., Xi, X.D., Liu, N.N., Li, Y.Z., Liu, Y.H., Yin, H.Q., Synthesis and antitumor activity of novel 2',3'-diethanethio-2',3',5'-trideoxy-5'-triazolonucleoside analogues. Eur. J. Med. Chem. 45 (2010), 3219–3222.
42. [22](b) Kumar, J.M., Idris, M.M., Srinivas, G., Kumar, P.V., Meghah, V., Kavitha, M., Reddy, C.V., Mainkar, P.S., Pal, B., Chandrasekar, S., Nagesh, N., Phenyl 1,2,3-triazole-thymidine ligands stabilize G-Quadruplex DNA, inhibit DNA aynthesis and potentially reduce tumor cell proliferation over 3′-azido deoxythymidine. PLoS ONE, 8, 2013, e70798.
43. [23] Miyakoshi, H., Miyahara, S., Yokogawa, T., Endoh, K., Muto, T., Yano, W., Ueno, T.Wakasa H., Chong, K.T., Taguchi, J., Nomura, M., Takao, Y., Fujioka, A., Hashimoto, A., Itou, K., Yamamura, K., Shuto, S., Nagasawa, H., Fukuoka, M., Synthesis and discovery of N-carbonylpyrrolidine- or N-sulfonylpyrrolidine-dontaining uracil derivatives as potent human deoxyuridine triphosphatase inhibitors. J. Med. Chem. 55 (2012), 6427–6437.
44. [24](a) Maračić, S., Gazivoda Kraljević, T., Čipčić Paljetak, H., Perić, M., Matijašić, M., Verbanac, D., Cetina, M., Raić-Malić, S., 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity. Bioorg. Med. Chem. 23 (2015), 7448–7463.
45. [24](b) Krištafor, S., Bistrović, A., Plavec, J., Makuc, D., Martinović, T., Kraljević Pavelić, S., Raić-Malić, S., One-pot click synthesis of 1,2,3-triazole-embedded unsaturated uracil derivatives and hybrids of 1,5- and 2,5-disubstituted tetrazoles and pyrimidines. Tetrahedron Lett. 56 (2015), 1222–1228.
46. [24](c) Korunda, S., Krištafor, S., Cetina, M., Raić-Malić, S., Conjugates of 1,2,3-Triazoles and acyclic pyrimidine nucleoside analogues: syntheses and X-ray crystallographic studies. Curr. Org. Chem. 17 (2013), 1114–1124.
47. [25] Batsanov, A.S., Collings, J.C., Fairlamb, I.J.S., Holland, J.P., Howard, J.A.K., Lin, Z., Marder, T.B., Parsons, A.C., Ward, R.M., Zhu, J., Requirement for an oxidant in Pd/Cu Co-catalyzed terminal alkyne homocoupling to give symmetrical 1,4-disubstituted 1,3-diynes. J. Org. Chem. 70 (2005), 703–706.
48. [26](a) Johnston, C.P., Kothari, A., Sergeieva, T., Okovytyy, S.I., Jackson, K.E., Paton, R.S., Smith, M.D., Catalytic enantioselective synthesis of indanes by a cation-directed 5-endo-trig cyclization. Nat. Chem. 7 (2015), 171–177.
49. [26](b) Du, W., Zhao, M.N., Ren, Z.H., Wang, Y.Y., Guan, Z.H., Copper-catalyzed 5-endo-trig cyclization of ketoxime carboxylates: a facile synthesis of 2-arylpyrroles. Chem. Commun. 50 (2014), 7437–7439.
50. [26](c) Alabugin, I.V., Gilmore, K., Finding the right path: Baldwin “Rules for Ring Closure” and stereoelectronic control of cyclizations. Chem. Commun. 49 (2013), 11246–11250.
51. [27](a) Kotora, M., Takahashi, T., Negishi, E.I., de Meijere, A., (eds.) Handbook of Organopalladium Chemistry for Organic Synthesis, 2002, Wiley-Interscience, New York, 973.
52. [27](b) Siemsen, P., Livingston, R.C., Diederich, F., Chem, Angew, Int, (eds.) Acetylenic Coupling: a Powerful Tool in Molecular Construction, vol. 39, 2000, 2632–2657.
53. [28](a) Kocaoba, S., Aydogan, F., Afsar, H., Potentiometric titration of some diamino compounds in toluene. Rev. Anal. Chem. 27 (2008), 263–271.
54. [28](b) Kocaoba, S., Aydogan, F., Afsar, H., No-aqueous titrations: potentiometric titration of some primary amines. Rev. Anal. Chem. 27 (2008), 123–130.
55. [29] Allen, F.H., The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr. B58 (2002), 380–388.
56. [30](a) Patil, K.R., Mohapatra, P., Patel, H.M., Goyal, S.N., Ojha, S., Kundu, C.N., Patil, C.R., Pentacyclic triterpenoids inhibit IKKβ mediated activation of NF-κB pathway: in silico and in vitro evidences. PLoS ONE, 10, 2015, e0125709.
57. [30](b) Filimonov, D.A., Poroikov, V.V., Varnek, A., Tropsha, A., (eds.) Chemoinformatics Approaches to Virtual Screening, 2008, RSC Publishing, Cambridge, UK, 182–216.
58. [31] Weisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., Nelson, E., Cowens, K., Christie, A.L., Mitsiades, C., Wong, K.K., Liu, Q., Gray, N., Griffin, J.D., Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia 29 (2015), 27–37.
59. [32] Hashimoto, O., Shinkawa, M., Torimura, T., Nakamura, T., Selvendiran, K., Sakamoto, M., Koga, H., Ueno, T., Sata, M., Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 19 (2006), 292–303.
60. [33](a) Leijen, S., Schellens, J.H., Shapiro, G., Pavlick, A.C., Tibes, R., Demuth, T., Viscusi, J., Cheng, J.D., Xu, Y., Oza, A.M., A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J. Clin. Oncol., 28, 2010, 3067.
61. [33](b) Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R.J., Collins, J., Chen, A.P., Doroshow, J.H., Kummar, S., Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J. Clin. Oncol. 33 (2015), 3409–3415.
62. [33](c) De Witt Hamer, P.C., Mir, S.E., Noske, D., Van Noorden, C.J., Würdinger, T., WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer. Res. 17 (2011), 4200–4207.
63. [34] Palmer, B.D., Thompson, A.M., Booth, R.J., Dobrusin, E.M., Kraker, A.J., Lee, H.H., Lunney, E.A., Mitchell, L.H., Ortwine, D.F., Smaill, J.B., Swan, L.M., Denny, W.A., 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J. Med. Chem. 49 (2006), 4896–4911.
64. [35] Kotelevets, N., Fabbro, D., Huwiler, A., Zangemeister-Wittke, U., Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis. PLoS One, 7, 2012, e39209.
65. [36] Pastukhov, O., Schwalm, S., Zangemeister-Wittke, U., Fabbro, D., Bornancin, F., Japtok, L., Kleuser, B., Pfeilschifter, J., Huwiler, A., The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death. Br. J. Pharmacol. 171 (2014), 5829–5844.
66. [37] Kogiso, T., Nagahara, H., Hashimoto, E., Ariizumi, S., Yamamoto, M., Shiratori, K., Efficient induction of apoptosis by Wee1 kinase inhibition in hepatocellular carcinoma cells. PLoS One, 9, 2014, e100495.
67. [38] Amacher, D.E., Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem. 12 (2005), 1829–1839.
68. [39] Marroquin, L.D., Hynes, J., Dykens, J.A., Jamieson, J.D., Will, Y., Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97 (2007), 539–547.
69. [40] Diffraction, Oxford, Xcalibur CCD System. 2012, CrysAlisPro, Agilent Technologies, Abingdon, England.
70. [41] Burla, M.C., Caliandro, R., Camalli, M., Carrozzini, B., Cascarano, G.L., De Caro, L., Giacovazzo, C., Polidori, G., Spagna, R., SIR2004: an improved tool for crystal structure determination and refinement. J. Appl. Crystallogr. 38 (2005), 381–388.
71. [42] Sheldrick, G.M., Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015), 3–8.
72. [43] Farrugia, L.J., WinGX and ORTEP for windows: an update. J. Appl. Crystallogr. 45 (2012), 849–854.
73. [44] Spek, A.L., Structure validation in chemical crystallography. Acta Crystallogr. D65 (2009), 148–155.
74. [45] Macrae, C.F., Bruno, I.J., Chisholm, J.A., Edgington, P.R., McCabe, P., Pidcock, E., Rodriguez-Monge, L., Taylor, R., van de Streek, J., Wood, P.A., Mercury CSD 2.0–new features for the visualization and investigation of crystal structures. J. Appl. Crystallogr. 41 (2008), 466–470.
75. [46] Gazivoda, T., Raić-Malić, S., Krištafor, V., Makuc, D., Plavec, J., Kraljević-Pavelić, S., Pavelić, K., Naesens, L., Andrei, G., Snoeck, R., Balzarini, J., Mintas, M., Synthesis, cytostatic and anti-HIV evaluations of the new unsaturated acyclic C-5 pyrimidine nucleoside analogues. Bioorg. Med. Chem. 16 (2008), 5624–5634.
76. [47] Andrae, D., Häussermann, U., Dolg, M., Stoll, H., Preuss, H., Energy-adjusted ab initio pseudopotentials for the second and third row transition elements. Theor. Chim. Acta 77 (1990), 123–141.
77. [48](a) Sikk, L., Tammiku-Taul, J., Burk, P., Computational study of copper-free sonogashira cross-coupling reaction. Organometallics 30 (2011), 5656–5664.
78. [48](b) García-Melchor, M., Pacheco, M.C., Nájera, C., Lledós, A., Ujaque, G., Mechanistic exploration of the Pd-catalyzed copper-free Sonogashira reaction. ACS Catal. 2 (2012), 135–144.
79. [48](c) Picek, I., Vianello, R., Šket, P., Plavec, J., Foretić, B., Tandem β-elimination/hetero-Michael addition rearrangement of an N-alkylated pyridinium oxime to an O-alkylated pyridine oxime ether: an experimental and computational study. J. Org. Chem. 80 (2015), 2165–2170.
80. [49] Fukui, K., The path of chemical reactions - the IRC approach Acc. Chem. Res. 14 (1981), 363–368.
81. [50] Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G.A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H.P., Izmaylov, A.F., Bloino, J., Zheng, G., Sonnenberg, J.L., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery, J.A. Jr., Peralta, J.E., Ogliaro, F., Bearpark, M., Heyd, J.J., Brothers, E., Kudin, K.N., Staroverov, V.N., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A., Burant, J.C., Iyengar, S.S., Tomasi, J., Cossi, M., Rega, N., Millam, J.M., Klene, M., Knox, J.E., Cross, J.B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R.E., Yazyev, O., Austin, A.J., Cammi, R., Pomelli, C., Ochterski, J.W., Martin, R.L., Morokuma, K., Zakrzewski, V.G., Voth, G.A., Salvador, P., Dannenberg, J.J., Dapprich, S., Daniels, A.D., Farkas, Ö., Foresman, J.B., Ortiz, J.V., Cioslowski, J., Fox, D.J., GAUSSIAN 09 (Revision A.02). 2009, Gaussian Inc., Wallingford CT.